Navigation Links
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
Date:11/14/2010

ased on the EPHESUS study population.

The primary objective of this trial is to evaluate the efficacy and safety of eplerenone plus standard heart failure (HF) therapy - including an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin receptor blockers (ARB), plus a beta–blocker – versus placebo plus standard HF therapy on the cumulative incidence of cardiovascular (CV) mortality and HF hospitalization (a composite primary endpoint).  The mean follow-up time was 21.1 months.

Patients were to be randomized (1:1) to receive eplerenone 25 mg once daily (OD) or matching placebo.  At four weeks, the dose of study drug could be increased to 50 mg OD (two 25mg tablets of eplerenone or two matching placebo tablets once daily) based on serum potassium level.  The trial was designed to enroll 3100 patients and to continue until a total of 813 adjudicated primary endpoint events were reported.

In May 2010, Pfizer announced that it planned to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC).  The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.

The study was funded by Pfizer.

About INSPRA®

INSPRA® (eplerenone) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone.  Eplerenone is thought to be a more selective blocker at the mineralcorticoid receptor since there is evidence that some of the effects result from a blockade of cortisol stimulation of the MR-receptor.

Important Prescribing Information

In the United States, Inspra® (eplerenone) is indicated to improve survival of st
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 Diabetes
2. TechniScan Announces Adding Another Center to Worldwide Clinical Trials for New Breast Imaging System
3. BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman
4. TMS Health Continues to Expand - Adding Over 60 New Jobs at Boca Raton Headquarters
5. Adding Steroid Drug to MS Treatment May Reduce Disease Activity
6. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
7. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
8. Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board
9. China Shenghuo Receives Notice from NYSE Amex LLC Regarding Listing Standards
10. Update: Clinical Trial Establishes Catheter-based Aortic Valve Replacement As New Standard of Care for Patients Who Cannot Undergo Surgery
11. Clinical Trial Establishes Catheter-Based Aortic Valve Replacement as New Standard of Care for Patients Who Cannot Undergo Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , April 28, 2015 Anteo Technologies ... powerful new tools developed with their patented Mix&Go™ ... coupling methods, helping to improve medical devices and ... Increasingly complex multifactorial diagnosis of cancer ... limits. It is restricted to measure only a ...
(Date:4/27/2015)... , April 27, 2015  Consumer Watchdog today ... bill that requires prescribers to check a state ... like OxyContin and other opioids – to help ... deaths. SB 482, authored by Sen. ... , will require prescribers to check Controlled ...
(Date:4/27/2015)... April 27, 2015 NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... in Boston, MA on Thursday, May ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
Breaking Medicine Technology:Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 2Faster Detection of Disease: Anteo is Transforming The Way Scientists Work with Luminex(R) xMAP(R) 3Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 2Consumer Watchdog Praises Passage of Bill that Requires Physicians Check Prescription Drug Database Before Prescribing Powerful, Addictive Medications 3NxStage to Present at the 40th Annual Deutsche Bank Securities Health Care Conference 2
... ,SARAH, - a French national collaborative randomized controlled ... sorafenib in advanced hepatocellular carcinoma is now open ... a new randomized controlled trial to directly compare ... (SIR-Spheres ® microspheres; Sirtex Medical Limited, Australia) ...
... 2, 2012  On February 2, at the Late-Breaking Science Session ... the TREVO Study ( T hrombectomy ... O cclusions in acute ischemic stroke). This ... clot-removing stent retriever technology. Sixty patients were enrolled by seven ...
Cached Medicine Technology:New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 2New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 3New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 4Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference 2
(Date:4/28/2015)... MO (PRWEB) April 28, 2015 The ... 2015 from 5:00 to 8:00 pm at the Sheraton Colonial ... than 50 hospitals, clinics and groups with career opportunities will ... represented. Attendees will enjoy free hors d’oeuvres and raffle prize ... PracticeMatch says “Boston is an ideal location to hold ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The west ... are among the top areas that healthcare professionals searched ... aureusmedical.com, during the month of March 2015. Data ... in travel nurse jobs , physical therapy ... within nursing and allied health fields. , ...
(Date:4/28/2015)... Foot and Ankle Specialists of the ... ( Annapolis and Clarksville Divisions ) was recently ... Maryland Podiatric Medical Association meeting on April 15, 2015. ... 1992 with a Bachelor of Arts in Life Sciences. ... soccer, track and cross-country. He then attended the New ...
(Date:4/27/2015)... VA (PRWEB) April 28, 2015 Medical ... **Presented by FDAnews and Ombu Enterprises**, June 16-17, 2015 ... an FDA inspector came to a facility today, would ... , If the answer is "maybe" or "no" … ... Enterprises and FDAnews have a solution. , Take ...
(Date:4/27/2015)... April 27, 2015 A new type of ... May 9. Science on Tap at the Science Museum of ... brews, but adds science hops for a bold, new flavor. ... trucks and serves up the science behind these frothy beverages. ... a first-hand look at the ingredients that go into beer ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3Health News:Hot States for Medical Careers: Healthcare Staffing Agency Aureus Medical Releases Online Search Results 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:Science on Tap at the Science Museum of Virginia 2
... KUNMING, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- ... Shenghuo" or,the "Company"), which is engaged in the research, ... products,in the People,s Republic of China ("PRC"), today reported ... 2009. , , Third Quarter 2009 ...
... resonance images (MRI) of patients diagnosed with multiple sclerosis ... more aggressive, and causes more brain lesions, than MS ... have reported. , Interestingly, however, patients with pediatric-onset MS ... MS cases -- develop disabilities at a slower pace ...
... to treatment for chlamydia, gonorrhea, syphilis is ,imperative, expert ... girls aged 15 to 19 accounted for the largest ... gonorrhea cases in the United States in 2008, followed ... annual federal report released Monday. , The researchers also ...
... ... to grant an ill child’s dream to go to Disneyland , ... (PRWEB) November 16, 2009 -- LeapFish has ... that dream come true. Tweet-a-Cause, a social media fundraising initative, will give Twitter users the ...
... 16 The nation,s premier public health agency, the Centers ... contract with Georgia Power to purchase renewable energy for its ... http://www.newscom.com/cgi-bin/prnh/20050216/CLW066LOGO ) , The purchase of more than ... organization,s annual kilowatt-hour consumption, will make the CDC Georgia Power,s ...
... A powerful new breast cancer treatment could result ... cancer,s hallmark wild growth with another that blocks a ... part of itself, researchers say. While they are ... called histone deacetylase inhibitors, or HDAC inhibitors, also increase ...
Cached Medicine News:Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 2Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 3Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 4Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 5Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 6Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 7Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 8Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 9Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 10Health News:China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009 11Health News:MS is more aggressive in children but slower to cause disability than in adults 2Health News:MS is more aggressive in children but slower to cause disability than in adults 3Health News:Teen Girls at Higher Risk for STDs: Report 2Health News:LeapFish and Make-a-Wish Foundation Join Forces to Raise $10,000 and Tweet an Ill Child's Wish True 2Health News:Georgia Power, Centers for Disease Control and Prevention Forge Green Energy Partnership 2Health News:New combination therapy could deliver powerful punch to breast cancer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: